Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Incyte exits cancer pact, leaving Agenus weighing its options
The termination will give Agenus full control of assets that it will consider advancing internally or through new partnerships.
Nick Paul Taylor
Feb 11, 2025 7:55am
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
Jan 10, 2025 6:45am
I-Mab pauses Sanofi-partnered prospect to focus on CLDN18.2
Jan 6, 2025 8:34am
Roche's TIGIT prospect fails another phase 3 lung cancer test
Nov 26, 2024 4:11am
Merck pays $588M for bispecific to defend Keytruda’s kingdom
Nov 14, 2024 7:45am
BioNTech pays $800M to take control of potential Keytruda killer
Nov 13, 2024 6:45am